EUVIMEDEUVIMED entdecken
Crossref

Factor XI deficiency and its management

Haider Rehan, Mehdi Asghar, Kumari Das Geetha, Ahmed Khanzada Zameer, Zameer Khanzada Sambreen

i-manager's Journal on Life Sciences · 2024

DOI: 10.26634/jls.3.1.20936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift i-manager's Journal on Life Sciences, 2024. Verfasst von Haider Rehan und 4 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Factor XI deficiency, also known as hemophilia C, is an uncommon bleeding disorder caused by insufficient levels of coagulation factor XI, a critical protein in the intrinsic pathway of blood clotting. Unlike hemophilia A and B, which involve deficiencies in factors VIII and IX respectively, factor XI deficiency typically results in milder bleeding. Managing factor XI deficiency requires a comprehensive approach that considers the severity of bleeding episodes, patient responses, and potential risks. Treatment options include factor replacement therapy, desmopressin (DDAVP), and antifibrinolytic medications tailored to meet each patient's specific needs. Factor replacement therapies involve administering plasma-derived or recombinant factor XI concentrates to elevate deficient levels and effectively prevent or treat bleeding events. However, challenges arise due to the limited availability of factor XI concentrates. DDAVP, a synthetic hormone, stimulates the release of stored factor XI from endothelial cells, rapidly increasing clotting levels. While effective in some cases, not all patients respond favorably to DDAVP therapy. Antifibrinolytic medications, such as tranexamic acid, stabilize blood clots by inhibiting fibrinolysis, offering additional protection against mucosal bleeding and during surgical procedures. Individualized treatment plans, daily monitoring of factor XI levels, and close collaboration among patients, hematologists, and healthcare providers are essential for effectively managing factor XI deficiencies. This paper aims to enhance understanding of this rare condition and develop innovative treatment strategies to improve the quality of life for individuals affected by factor XI deficiencies.

Zitieren

APA

Rehan, H., Asghar, M., Geetha, K. D., Zameer, A. K., & Sambreen, Z. K. (2024). Factor XI deficiency and its management. i-manager's Journal on Life Sciences. https://doi.org/10.26634/jls.3.1.20936

Vancouver

Rehan H, Asghar M, Geetha KD, Zameer AK, Sambreen ZK. Factor XI deficiency and its management. i-manager's Journal on Life Sciences. 2024. doi:10.26634/jls.3.1.20936

BibTeX
@article{Rehan2024,
  author = {Rehan, Haider and Asghar, Mehdi and Geetha, Kumari Das and Zameer, Ahmed Khanzada and Sambreen, Zameer Khanzada},
  title = {Factor XI deficiency and its management},
  journal = {i-manager's Journal on Life Sciences},
  year = {2024},
  doi = {10.26634/jls.3.1.20936}
}
Kostenlos starten →